Navigation Links
Collegium Pharmaceutical Names Douglas Carlson to Vice President of Business Development
Date:4/3/2013

CANTON, Mass., April 3, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, has hired Douglas Carlson in the newly-created position of Vice President of Business Development.

Doug previously held the position of Senior Director, Business Development at BTG International Inc., where he was responsible for global specialty pharmaceutical M&A and licensing. Prior to BTG International, Doug spent nearly five years at Ovation Pharmaceuticals, Inc. where he advanced from Manager of Business Development to Senior Director of Corporate Business Development and Strategy, and played a pivotal role in the sale of Ovation to H. Lundbeck A/S resulting in a $900 million acquisition. Prior to Ovation, Doug was an Associate in the healthcare group at Pequot Ventures, the venture capital arm of Pequot Capital Management, Inc. Doug started his career in the healthcare investing banking group SG Cowen & Co. He received a Bachelor of Arts degree in American Studies from Trinity College in Hartford, Connecticut and completed a post-graduate advanced studies program at Oxford University.

"Collegium's lead development program, Oxycodone DETERx®, leverages the Company's abuse-deterrent technology platform in an area with significant unmet medical need. I am incredibly excited to be joining Collegium as the Company brings its first product closer to FDA approval," states Doug Carlson .     

"As we rapidly advance Oxycodone DETERx® towards an NDA filing within the next 12 months, we will be initiating a process to identify potential commercial partners for both the U.S. and international markets. We are excited to have a person with Doug's experience and background joining the team at this important time for the Company," states Michael Heffernan , CEO of Collegium.

About DETERx® Technology

The DETERx® drug delivery platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide abuse-deterrent properties to protect against common methods of tampering such as chewing, crushing, insufflation and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents on food or via a gastronomy tube, while maintaining the extended-release properties of the product. DETERx® technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. COL-003 is the first of a number of product candidates using the DETERx® platform.

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® formulation platform for the treatment of chronic pain. The DETERx® oral drug delivery technology provides extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. For more information, visit the Company's website at www.collegiumpharma.com.

Contact:

Michael Heffernan , President
Collegium Pharmaceutical, Inc.
781.713.3699
mheffernan@collegiumpharma.com


'/>"/>
SOURCE Collegium Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Collegium Pharmaceuticals CEO to Present at the Cowen & Company 33rd Annual Health Care Conference in Boston on March 6, 2013
2. Collegium Pharmaceutical Announces Relocation to Massachusetts
3. Collegium Pharmaceutical to Present at Piper Jaffrays 24th Annual Healthcare Conference
4. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
5. European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6 Billion by 2017
6. China Botanic Pharmaceutical Inc. Announces Receipt of Notice of Failure to Satisfy Continued Listing Letter
7. AG Mednet and Japans Biovisiq Bring Zero-Delay Clinical Trial Solutions to Asian Pharmaceutical Market
8. Everyday Health Expands Solutions For Pharmaceutical Industry Marketers
9. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
10. Valeant Pharmaceuticals Announces Private Exchange Offer
11. Pull-Through Programs Critical for Maintaining Demand for Pharmaceutical Products on Managed Care Formularies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ANGELES (PRWEB) , ... October 12, 2017 , ... ... Parsa Mohebi Hair Restoration, has recently contributed a medical article to the newly ... on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
Breaking Medicine News(10 mins):